Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Figures & data

Table I. Kaplan-Meier curves of time to progression (median 8.3 months; 95% CI 5.1–9.3 months) and overall survival (median 12.0 months; 95% CI 8.9–14.1 months).

Characteristic	All
Numbers	27
Age, years (median, range)	62 (35–80)
Sex (male/female)	16/11
WHO performance status 0–1	25
WHO performance status 2	2
Duration of prior therapy
Duration of 1. line therapy, months (median, range)	5.5 (2–13)
Duration of 2. line therapy, months (median, range)	4.2 (2–16)
Duration of 3. line therapy with cetuximab and irinotecanmonths (median, range)	8.8 (4–17)
Response rate to cetuximab and irinotecan (95% CI)	22%
Time from non-resectable disease to indication for cetuximab, irinotecan and bevacizumab, month (range)	31.5 (18–69)
Time from last treatment with cetuximab and irinotecan, to the first treatment with cetuximab, irinotecan and bevacizumab, months (range)	2.4 (0.5–10)

Table II. Toxicity of treatment with biweekly cetuximab, irinotecan and bevacizumab.

Toxicity	Grade
	2	3 or 4
Skin (%)	42	8
Nail (%)	12	0
Diarrhea (%)	8	4
Nausea (%)	4	0
Vomiting (%)	4	0
Fatigue (%)	36	4
Neutropenia (%)	0	4
Thrombocytopenia (%)	0	0
Anaphylactic reaction (%)	0	0
Hypertension	0	0
Thromboembolic events	0	0

Figure 1. Time to progression and overall survival.

Table III. Efficacy data for patients receiving cetuximab, irinotecan and bevacizumab (CIB) as fourth line therapy.

Characteristic	All	KRAS MUT	KRAS WT
Number of patients	27	13	13
Response rate
Partial response (PR)	2 (7 %)	0	2 (15%)
Stable disease (NC)	17 (63%)	8 (62%)	8 (62%)
Disease control (CR + PR + NC)	19 (70%)	8 (62%)	10 (77%)
Progression (PD)	5 (19%)	3 (23%)	2 (15%)
Not evaluable	3 (11%)	2 (15%)	1 (8%)
Median duration of therapy with CIB months (range)		4.3 (0–13)	8.2 (0–28)
Median number of CIB	11 (1–56)	7 (1–44)	16 (1–56)
PFS, months (95% CI)	8.3 (3–11)	5.1 (3–9)	8.9 (5–11)
OS, months (95% CI)	12.0 (5–15)	9.0 (5–14)	12.7 (9–15)